Structure-based discovery of fiber-binding compounds that reduce the cytotoxicity of amyloid beta

被引:110
|
作者
Jiang, Lin
Liu, Cong
Leibly, David
Landau, Meytal
Zhao, Minglei
Hughes, Michael P.
Eisenberg, David S. [1 ]
机构
[1] Univ Calif Los Angeles, Howard Hughes Med Inst, Dept Chem & Biochem, UCLA DOE Inst Genom & Prote, Los Angeles, CA 90024 USA
来源
ELIFE | 2013年 / 2卷
基金
美国国家卫生研究院;
关键词
SMALL-MOLECULE INHIBITORS; PROTEIN AGGREGATION; ALZHEIMERS-DISEASE; CONGO RED; OLIGOMERS; PEPTIDE; STRATEGIES; NEUROTOXICITY; FIBRILS; DOCKING;
D O I
10.7554/eLife.00857
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Amyloid protein aggregates are associated with dozens of devastating diseases including Alzheimer's, Parkinson's, ALS, and diabetes type 2. While structure-based discovery of compounds has been effective in combating numerous infectious and metabolic diseases, ignorance of amyloid structure has hindered similar approaches to amyloid disease. Here we show that knowledge of the atomic structure of one of the adhesive, steric-zipper segments of the amyloid-beta (A beta) protein of Alzheimer's disease, when coupled with computational methods, identifies eight diverse but mainly flat compounds and three compound derivatives that reduce A beta cytotoxicity against mammalian cells by up to 90%. Although these compounds bind to A beta fibers, they do not reduce fiber formation of A beta. Structure-activity relationship studies of the fiber-binding compounds and their derivatives suggest that compound binding increases fiber stability and decreases fiber toxicity, perhaps by shifting the equilibrium of A beta from oligomers to fibers.
引用
收藏
页数:27
相关论文
共 50 条
  • [1] Structure-based discovery of fiber-binding compounds that reduce the cytotoxicity of amyloid beta (vol 2, e00857, 2013)
    Jiang, Lin
    Liu, Cong
    Leibly, David
    Landau, Meytal
    Zhao, Minglei
    Hughes, Michael P.
    Eisenberg, David S.
    ELIFE, 2013, 2
  • [2] Structure-Based Peptide Design to Modulate Amyloid Beta Aggregation and Reduce Cytotoxicity
    Kumar, Jitendra
    Namsechi, Risa
    Sim, Valerie L.
    PLOS ONE, 2015, 10 (06):
  • [3] Structure-based screening for discovery of sweet compounds
    Ben Shoshan-Galeczki, Yaron
    Niv, Masha Y.
    FOOD CHEMISTRY, 2020, 315
  • [4] Amyloid beta: structure, biology and structure-based therapeutic development
    Chen, Guo-fang
    Xu, Ting-hai
    Yan, Yan
    Zhou, Yu-ren
    Jiang, Yi
    Melcher, Karsten
    Xu, H. Eric
    ACTA PHARMACOLOGICA SINICA, 2017, 38 (09) : 1205 - 1235
  • [5] Amyloid beta: structure, biology and structure-based therapeutic development
    Guo-fang Chen
    Ting-hai Xu
    Yan Yan
    Yu-ren Zhou
    Yi Jiang
    Karsten Melcher
    H Eric Xu
    Acta Pharmacologica Sinica, 2017, 38 : 1205 - 1235
  • [6] Structure-Based discovery of actin-binding drugs
    Allendorf, Scout
    Wilson, Anna
    Nair, Chandini
    Thomas, David D.
    Guhathakurta, Piyali
    BIOPHYSICAL JOURNAL, 2022, 121 (03) : 255A - 255A
  • [7] Structure-based inhibition of amyloid beta-protein oligomerization
    Bitan, G
    GERONTOLOGIST, 2005, 45 : 55 - 55
  • [8] Structure-based inhibitor design and discovery against beta-lactamase.
    Shoichet, B
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2002, 223 : U479 - U479
  • [9] Structure-based shape pharmacophore modeling for the discovery of novel anesthetic compounds
    Ebalunode, Jerry O.
    Dong, Xialan
    Ouyang, Zheng
    Liang, Jie
    Eckenhoff, Roderic G.
    Zheng, Weifan
    BIOORGANIC & MEDICINAL CHEMISTRY, 2009, 17 (14) : 5133 - 5138
  • [10] Structure-based discovery and binding site analysis of histamine receptor ligands
    Kiss, Robert
    Keseru, Gyorgy M.
    EXPERT OPINION ON DRUG DISCOVERY, 2016, 11 (12) : 1165 - 1185